The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7184-7188

  Moasser, Mark M ^a   Basso, Andrea ^b   Averbuch, Steven D ^c,d   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Medical Center   (United States)

^c ASTRAZENECA   (United Kingdom)

^d Macclesfield DGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG ACTIVITY; DRUG SENSITIVITY; ENZYME ACTIVITY; EPITHELIUM TUMOR; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; DOWN-REGULATION; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0035476803     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. The ErbB signaling network: Receptor heterodimerization in development and cancer
2. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
3. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
4. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
5. Development of mammary hyperplasia and neoplasia in MMTV-TGF α transgenic mice
6. Protein tyrosine kinase growth factor receptors and their ligands in development, differentiation, and cancer
7. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
8. Herceptin (trastuzamab) in advanced breast cancer
9. The epidermal growth factor receptor and its inhibition in cancer therapy
10. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI), shows evidence of good tolerability and activity: Final results from a Phase I study
11. Phase I study of oral ZD1839, a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity
12. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
13. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family
14. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-α bigenic mice
15. Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation
16. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor
17. The epidermal growth factor receptor associates with and recruits phosphatidylinositol 3-kinase to the platelet-derived growth factor β receptor
18. A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling
19. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase
20. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-Her2 monoclonal antibody Herceptin in Her2-overexpressing metastatic breast cancer